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Pancreatico-duodenal tumors are the second most common endocrinopathy in multiple endocrine neoplasia
syndrome type 1, and have a pronounced effect on life expectancy as the principal cause of disease-related death.
Previous discussions about surgical management have focused mainly on syndromes of hormone excess and, in
particular, the management of multiple endocrine neoplasia syndrome type 1-related Zollinger–Ellison syndrome.
Since hormonal syndromes tend to occur late and indicate the presence of metastases, screening with biochemical
markers and endoscopic ultrasound is recommended for early detection of pancreatico-duodenal tumors, and with
early surgery before metastases have developed. Surgery is recommended in patients with or without hormonal
syndromes in the absence of disseminated liver metastases. The suggested operation includes distal 80% subtotal
pancreatic resection together with enucleation of tumors in the head of the pancreas, and in cases with Zollinger–
Ellison syndrome, excision of duodenal gastrinomas together with clearance of regional lymph node metastases.
This strategy, with early and aggressive surgery before metastases have developed, is believed to reduce the risks for
tumor recurrence and malignant progression.
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is an
autosomal dominant hereditary syndrome with high pene-
trance, where 50% of children of an affected parent inherit the
trait, and virtually all gene carriers develop features of the
syndrome (1–3). The syndrome is rare, with a prevalence of
two or three cases per 100,000 population, being equally
common in males and females (2,3). MEN1 patients classically
present with tumors of the parathyroid, the endocrine
pancreas/duodenum and the anterior pituitary. The trait also
implies increased risk of adrenocortical lesions (with hyper-
plasia, adenoma, rarely carcinoma in up to 30% of patients),
increased incidence of foregut carcinoids (occurring in 7%, in
the thymus, bronchial tree, and the stomach), and lower
incidence of multiple lipoma, ependymoma, leiomyoma,
meningeoma, facial angiofibroma, and collagenoma (2–5).
Genetic diagnosis
MEN1 is caused by inactivating mutations of the MEN1
tumor suppressor gene on chromosome 11q13, germline
mutation has inactivated one allele, and tumors occur when
the second allele is silenced by somatic mutation. The gene
encodes for Menin, with an important role for DNA
replication and transcriptional regulation (6). The gene is
complex, with more than 1,000 identified mutations, with-
out strong genotype–phenotype correlations and also with
variable disease expression within families (7). Genetic
diagnosis is obtained by complete MEN1 gene sequencing,
which can reveal mutations in 70–90% of typical MEN1
cases, and a recently introduced multiplex ligation-depen-
dent assay (MLPA), which can detect large deletions in
another 4% (8). If mutation is unknown in the family, the
genetic diagnosis can be difficult and negative genetic
testing cannot exclude the syndrome. Without positive
genetic diagnosis, MEN1 is clinically diagnosed if a patient
has tumors in two of the three classical endocrine organs
(parathyroid, pancreas/duodenum, or pituitary), or has
family history of MEN1 and one such tumor (2).
Genetic family screening is important since unaffected
family members may be spared unnecessary investigations
and anxiety (3). Screening for MEN1 endocrine tumors is
recommended in gene carriers, since biochemical abnorm-
alities can often be revealed decades before clinical
symptoms appear (2,9). If screening is delayed until clinical
symptoms develop, morbidity and mortality may be
encountered, especially from neuroendocrine pancreatico-
duodenal (NEN-PET) and thymic tumors (2,3,9–11).
Screening to reveal any of the three classical endocrinopa-
thies should begin in children during the first decade of life
(Table 1) (11,12).
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It is most important to emphasize that primary hyperpar-
athyroidism (pHPT) has been the most common and
generally the first detected endocrinopathy in MEN1, often
diagnosed at ,20 years of age, and affecting more than 95%
of patients at 40 years of age (2,3,9–12). MEN1-pHPT is
typically associated with hyperplasia/multiglandular para-
thyroid disease, and should be suspected in all cases with
multiglandular involvement or recurrent HPT (13). Younger
HPT patients (,40 years) may often (,10%) be index cases
for MEN1 kindreds, and are liberally subjected to parathyr-
oid surgery due to long-term risk for osteoporosis and renal
complications (2,9–16). The presence of the MEN1 syndrome
may be revealed by screening with serum calcium or careful
penetration of the family history in patients with pancreatico-
duodenal tumors, pituitary tumors, or foregut carcinoids
(2,3,9,11). Hypercalcemia caused by HPT stimulates gastrin,
and early parathyroid surgery is recommended in patients
with MEN1-associated Zollinger–Ellison syndrome (ZES),
together with liberal use of proton pump inhibitors (PPIs)
(16,17).
Pancreatico-duodenal neuroendocrine tumors
(PETs)
PETs are the second most common endocrinopathy in
MEN1, with a prevalence of 35–40% at the age of 50 years,
with higher figures if patients are subjected to more careful
screening programs (2,3,11,18,19). Rarely, patients will have
PETs as the first endocrinopathy recognized in childhood.
The MEN1 endocrinopathy consists of numerous micro-
adenomas typically spread throughout the entire pancreas,
which vary in size from slightly larger than a normal islet to
a few millimeters in diameter, and with generally only few
concomitant larger tumors (2,3,8,9,11,20,21). Pancreatic islets
of normal size, cell morphology, and arrangement invari-
ably surround the microtumors and often occur together
with areas of nesidioblastosis with exocrine duct prolifera-
tions, and clusters of endocrine cells, which has been
claimed to support the origin of microadenomas from
pancreatic duct precursor cells rather than the pancreatic
islets (2,11,21). Microtumors lack the normal islet cell
organization, and frequently show immunoreactivity for
multiple hormones, most commonly pancreatic polypeptide
(PP), but there may also be reactivity for glucagon, insulin,
proinsulin, somatostatin, or sometimes only chromogranin
A (21,22). Duodenal microtumors, which have been identi-
fied in 50% of patients with the endocrinopathy, stain for
serotonin, gastrin, and somatostatin (23). Gastrin immunor-
eactivity has generally been absent in pancreatic micro-
adenomas, and only occasionally demonstrated in larger
pancreatic tumors (21), in which PP or only chromogranin A
reactivity has been most common (2,21). The presence of
endocrinopathy can be diagnosed by serum measurements
of pancreatic hormones even in the absence of a syndrome
of hormone excess, most commonly showing raised serum
values of PP and chromogranin A, sometimes gastrin,
insulin and proinsulin, occasionally glucagon, vasoactive
intestinal peptide (VIP) or calcitonin (2,4,11). Only a
minority of the microtumors acquire the potential to grow
to clinically relevant lesions, since each patient will during
their lifetime experience only few large tumors (2,4,11,18).
Cure requires total pancreatico-duodenectomy, which is
rarely considered as initial procedure because of significant
morbidity and mortality associated with resulting severe
diabetes and exocrine pancreatic insufficiency (2,3,11).
Extended survival has been reported in MEN1 patients
with PETs, even in the presence of metastases, suggesting
that the disease may often have an overall indolent course.
However, disease progression varies widely between and
within families, and individual patients have PETs with
exceedingly more malignant behavior (2,4,19). Although
suggested by some authors, no convincing and confirmed
genotype–phenotype relationships have yet been demon-
strated (2,4,9,19,24). The MEN1 PETs have been claimed to
have favorable prognosis compared with sporadic tumors,
though earlier diagnosis of MEN1 tumors, or in case of ZES,
disparate survival for patients with duodenal and pancrea-
tic gastrinomas, appear to explain this difference (11,21,25).
With adjustment for younger age due to screening detection
in MEN1, similar survival expectancy has been revealed for
MEN1-associated and sporadic PETs (11,21,25).
Malignant progression of PETs and thymic carcinoids has
been the principal cause of premature disease-related death
in MEN1, and the pancreatic malignancy has been identified
as the major cause of death, with nearly half of affected
patients dying before 50 years of age, mainly with liver
metastases (2,9,11,26–29). When first recognized in 1989 that
duodenal gastrinomas was the most common cause of
MEN1 ZES, Norman Thompson introduced the procedure
for distal, subtotal (80–85%) pancreatic resection, together
with enucleation of pancreatic head tumors, duodenotomy
for excision of duodenal gastrinomas and careful dissection
of lymph gland metastases around the pancreatic head
(11,30,31). In our experience, PETs could be detected by
biochemical screening decades before development of a
clinical syndrome of hormone excess (such as ZES), and we
have suggested earlier surgery for malignancy prevention,
not only in the MEN1 ZES patients, but also in patients with
non-functioning MEN1 lesions (2,3,9,11,18,32). Screening
studies revealed that 30–50% of patients already had
metastases when a clinical syndrome of hormone excess,
most often ZES, had developed, and for two decades we
have therefore recommended timely repeated biochemical
screening for PETs in MEN1 carriers to achieve early
diagnosis, and early surgery for malignancy prevention
Table 1 - MEN1 screening. Revised from Brandi et al (12).
Tumor Age that screening began (years) Biochemical tests (annually)
Imaging
(every 3 years)
Parathyroid 10 Serum calcium (PTH) None
Gastrinoma 20 Serum gastrin None
Insulinoma 5 Fasting serum glucose/insulin/proinsulin None
Non-functioning PETs 20 PP, proinsulin, insulin, glucagon, VIP, chromogranin A Endoscopic US (OctreoScan,
CT)
Anterior pituitary 5 Prolactin, IGF-1 Brain MRI
Foregut carcinoid 20 None CT
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(2,3,9,11,18,20,21,29,32). Consequently, in our center, the
non-functioning PETs have become the most common
tumor entity requiring surgery in ,50% of MEN1 patents
(19,29,32).
Surgery for non-functioning PETs
Raised biochemical markers, especially serum PP values,
have together with raised values of chromogranin A become
increasingly important for early detection of non-function-
ing PETs (2,3,9,11,29,32). Patients may also have raised
insulin/proinsulin, glucagon, VIP or calcitonin values,
without a hormone excess syndrome. Most authors agree
that patients with non-functioning tumors larger than 2–
3 cm should undergo surgery, but the size limit has been the
subject of controversy (19). Studies of non-functioning
MEN1 PETs in the French GTE register revealed a low
(4%) metastases rate for tumors #10 mm, and notably
higher metastases rate (15–52%) for larger tumors (33–35).
However, reporting a 15% mortality risk from pancreatic
surgery, the authors recommended surgery for non-func-
tioning PETs greater than or equal to 2 cm (33–35). We and
other authors recommend surgery for non-functioning
MEN1 PETs around or greater than 10 mm, since the
metastases rate is unacceptably high for larger tumors, and
surgery has been carried in rather large series without
mortality (11,19,36,37).
Before surgery, contrast-enhanced computed tomogra-
phy (CT) is routinely performed to clarify the anatomy and
possible presence of liver metastases (11). C-5-hydroxy-
tryptophane (5HTP)-positron emission tomography (PET)
has been efficiently used in our department to reveal small
PETs and lymph node metastases (38). Endoscopic ultra-
sound (EUS) has become the most important method for
early detection of PETs, with the ability to show the
relation to the pancreatic and the bile ducts, and is now
used for routine screening follow-up of MEN1 patients
(11,19,36,37,39).
The surgical procedure generally consists of distal 80%
subtotal pancreatic resection with the pancreas divided to
the left of the portal vein, and enucleation of possible
pancreatic head tumors. Occasionally patients present with
larger or multiple tumors, and more extensive procedures
may be required. Smaller tumors (,5 mm) deep in the
pancreatic head, or close to the bile or pancreatic ducts, are
left if enucleation is considered hazardous. Duodenotomy is
not done in patients without a rise in serum gastrin.
Surgery for PETs with syndromes of hormone excess
ZES has been the most common hormone syndrome in
MEN1, which ultimately may be present in 30–50% of
patients, and implies that 30% or more of ZES patients have
the MEN1 syndrome (2,3,11,19,36). Insulinoma causing the
hypoglycemia syndrome has been revealed in 4–10%,
vipoma in 3–5% and symptomatic glucagonoma has been
exceptionally rare (,1%) (2,3,11,19,36).
Surgery for insulinomas, vipomas and
glucagonomas
There is general consensus to submit MEN1 patients with
insulinoma and a hypoglycaemia syndrome to surgery after
biochemical diagnosis and fasting test verification, more or
less irrespective of tumor size, since no efficient medical
treatment option is available (2,11,18,19,39–43).
In patients with hypoglycaemia, a single tumor $5 mm is
expected to cause hyperinsulinism, and the tumor can often
be revealed by EUS. Non-functioning tumors may, however,
occur concomitantly and the source of insulin (or proinsu-
lin) excess may occasionally have to be determined by
selective intra-arterial calcium-injection test (SAS test),
which can regionalize the hypersecretion and identify rare
multifocal insulinomas (11,41). Favorable cure rate after
surgery has been reported in patients with MEN1 insulino-
mas, but concomitant distal (80%) pancreatic resection is
recommended to remove concomitant non-functioning
tumors and minimize risk of recurrence (11,19,40–42).
Tumor enucleation has only been reported with increased
risk for recurrence of non-functioning tumors or new
insulinoma (2,11,19,40–42). The most important is to
emphasize that the malignancy rate is higher with MEN1
associated than with sporadic insulinoma, and may be
recognized by metastases with also moderately large MEN1
insulinomas (11).
Rare MEN1 patients with vipoma or glucagonoma
syndromes usually present with large PETs with high risk
of malignancy, and should be treated with radical surgery
(11,19,44,45). Due to severe hormone symptoms, patients
with these tumors may require liver resection, treatment
with repeated radiofrequency (RF) ablation or even resec-
tion of lung metastases (46).
Surgery for ZES
For MEN1 ZES patients surgery remains controversial
because persistent normalization of raised gastrin levels is
rarely achieved, and long survival can also be expected
without operation (2,3,11,19,47,48). Some surgeons have
advocated surgery when gastrin excess could be regiona-
lized by the SAS (Imamura) test, others only when tumors
.2–3 cm have been visualized (30,31,48–50).
We have also proposed surgery in the absence of liver
metastases without pre-operative tumor localization or
regionalization, since the vast majority (,90%) of MEN1
ZES patients have single, or multiple, small duodenal
tumors as the cause of gastrin excess, and smaller tumors
generally require duodenotomy for visualization (2,11,
21,23,30,31). Also, the smaller duodenal tumors are often
associated with conspicuously larger regional lymph node
metastases which may easily be mistaken for the primary
tumor when occurring within the peripancreatic fasciae
capsule (11,51). Ultimately, there is often delay before liver
metastases develop in ,10–20% of patients, which may
provide a favorable interval for intervention, where lymph
node metastases may be excised together with the primary
lesion (11,52). Gastrin-secreting pancreatic tumors are
uncommon in MEN1, but have been reported to be large
and they may be associated with earlier liver metastases, as
reported for patients with sporadic pancreatic gastrinoma
(19,50). Survival is favorable in patients with small
duodenal gastrinomas, even in the presence of lymph node
metastases, but is worse for patients with larger duodenal or
pancreatic gastrinomas (19). Surgical excision of gastrinoma
and lymph gland metastases may normalize gastrin excess,
but the effect is time-limited, since virtually all patients will
recur with hypergastrinemia, sometimes after several years’
delay (3,11,19,47,48,53,54). Since ZES patients with liver
metastases have significantly shorter survival, and liver
metastases possibly develop less frequently in operated
patients, we perform surgery to reduce the risk of further
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progression (3,11,19,50,53). Milder recurrent hypergastrine-
mia in ZES can be efficiently controlled by PPI, and surgery
has in our opinion the additional important goal to delay
malignant development, also by removal of concomitant
non-functioning tumors (2,3,11,18). Non-functioning tumors
of conspicuous size have in our experience been almost
invariably present when MEN1 patients have been sub-
jected to surgery with ZES, and may be a more likely cause
of spread with liver metastases.
Our general policy is to subject MEN1 patients with
raised serum gastrin and ZES verified by gastric acid
hypersecretion (pH,2 in gastric aspirate) to exploration
with duodenotomy for visualization (palpation is essential)
of single or multiple duodenal gastrinomas. Distal (80%)
pancreatic resection is carried out for removal of concomi-
tant non-functioning tumors together with careful dissection
of regional metastases, and enucleation of possible tumors
in the head of the pancreas (3,11,18).
Pancreatico-duodenectomy (PD) has been performed in
limited series of MEN1 patients and shown to offer better
possibilities for cure of ZES in selected patients than
excision of duodenal gastrinomas combined with subtotal
pancreatic resection (3,11,19,37,43). However, in our experi-
ence concomitant non-functioning tumors have virtually
always necessitated distal pancreatic resection in the ZES
patients (3,11,18) Moreover, if reoperation is required for
recurrent pancreatic tumor this may be exceedingly difficult
after previous pancreatico-jejunostomy as part of PD. After
PD, treatment of liver metastases with embolization or RF
ablation may be hazardous and should be avoided due to
risk for serious ascending infection via the hepatico-
jejunostomy (46). Still PD is occasionally required as the
primary procedure in MEN1 patients with a large pancrea-
tic head or duodenal tumors, and sometimes also required
at reoperation for recurrent duodenal or pancreatic head
tumors (55). In our experience such recurrences have been
treated with re-resection of the pancreatic neck or new
enucleations rather than total pancreatectomy, but this may
ultimately be required (55). Pancreas-preserving duodenect-
omy has been reported as an elegant technique to remove
multiple duodenal gastrinomas entirely, but it is a difficult
procedure suggested to benefit selected patients with
multifocal duodenal gastrinomas, with the problem of
leaving behind the possible common concomitant non-
functioning pancreatic tumors (56–58).
High gastrin and long-standing gastrin excess may, in 5–
30% of MEN1-ZES patients, result in development of type 2
gastric carcinoids in the gastric body and fundus and
occasionally in the antrum (51). These tumors are generally
multiple and often larger than 1.5 cm, and may occupy
virtually the entire fundic mucosa. Occasional tumors are
larger (.4 cm). Lymph node metastases occur in ,30%, and
liver metastases in 10–20%. Smaller lesions may sometimes
regress if eugastrinemia is achieved, and the remaining
tumors should be locally excised (59). Some MEN1 patients
have died from such malignant gastric carcinoids with
metastases, and therefore gastrectomy may sometimes be
required for the large gastric carcinoids (59,60).
Technical aspects of MEN1 pancreatico-duodenal
exploration
In MEN1 patients the entire pancreas is explored by
bilateral subcostal incision. The duodenum and the pancrea-
tic head are mobilized with ventral and dorsal surfaces
dissected to the aorta. The pancreatic tail and body are
explored via the lesser sack, with retroperitoneum incised
below the pancreas, to allow blunt dissection of the distal
parts. The entire pancreas is bidigitally palpated and scanned
with intraoperative ultrasonography (IOUS), revealing
lesions larger than 3-4 mm, and facilitating safe enucleation
by showing relations between tumors and ductal structures
(2,3,11). Metastatic lymph glands are searched for around the
splenic and celiac vessels, in the hepatoduodenal ligament,
and especially within the dorsal fasciae capsule of the
pancreatic head.
A pancreatic head tumor is generally enucleated by
cautious dissection with careful ligation/clipping of vessels
and any pancreatic duct tributaries. A distal 80% body and
tail resection is undertaken by transecting the pancreatic
neck to the left of the porto-mesenteric vein. Any enucleated
area in the pancreatic head is left open, with drainage
carefully applied.
Since the majority of MEN1 patients require prophylactic
cancer operation, and efficient removal of lymph node
metastases, with predilection in the hilus of the spleen,
splenectomy rather than spleen preservation is generally
recommended.
Duodenotomy is more efficient than duodenoscopy or
EUS to visualize gastrinomas in MEN1-ZES, which can
be multiple in ,50% of patients (58). Routine duodenal
exploration is performed in patients with the ZES syn-
drome via longitudinal duodenotomy in the descending
part of the duodenum. Even small tumors can be identified
by palpation after digital inversion of the proximal and
distal parts of the duodenum. Duodenal tumors smaller
than 5 mm can be enucleated with the mucosa; larger
tumors require limited excision of the duodenal wall.
Postoperative follow-up/reoperation. Surgery for the
MEN1 pancreatico-duodenal endocrinopathy rarely results
in lifelong cure, and recurrence should be expected
(2,3,11,19,53,54). The patients should be subjected to, in
general, yearly follow-up with biochemical markers and
radiological investigations, including EUS. Reoperation
is considered when a lesion of arbitrarily ,10 mm is
visualized concomitant with a rise in biochemical markers,
or a patient develops a clinical syndrome of hormone
excess. Reoperations have in our experience been mainly
performed as resections or enucleations of new tumors, and
have been uncomplicated and compatible with long
survival and generally preserved pancreatic function. We
have experienced no mortality, or pancreatic fistulas
requiring reoperation, after primary or reoperative surgery
in our MEN1 PETs patients. Total pancreatectomy may be
required for recurrent, rapidly growing, or unusually large
tumors, and is even considered when there is a strong
history of markedly malignant pancreatic tumors in the
family (2,3,11,55). We have with few exceptions avoided
this, due to the resulting generally severe diabetes that
ensues, and complete removal of the pancreatic head and
duodenum to achieve total pancreatectomy, after previous
subtotal pancreatic resection, has, according to reports from
other groups, sometimes been difficult or complicated
(19,54). Liver metastases are treated with liver resection
when possible, and RF ablation. In patients with unre-
sectable liver spread or other distant metastases, oncologic
treatment is given, with a common response to combi-
nations of streptozotocin and 5-fluorouracil or doxorubicin;
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recently radioreceptor therapy with Luthetium has also
been considered.
Several patient series support the active management
strategy for MEN1 PETs by reporting reduced death risk in
operated patients (19,24,37,43,54,56–58,61–63). However,
strong evidence for an improvement in survival is lacking.
It is crucial to emphasize that liberal indications for
pancreatico-duodenal surgery, and aggressive resection
surgery, have to be undertaken cautiously with low
morbidity and virtually absent mortality, since extended
survival can often be expected without surgery (11,55,61,64).
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